NCT02208934View on ClinicalTrials.gov

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Huntington's Disease

Interventions

DRUG

PBF-999

5, 10, 20 and 40 mg of PBF-999

DRUG

Placebo

Placebo for all dosis of PBF-999

Trial Locations (2)

08025

CIM-Sant Pau - IIB Sant Pau, HSCSP, Barcelona

08302

Palobiofarma S.L. (molecule owner), Mataró

Sponsors

Collaborators (1)

Palo Biofarma, S.L

All Listed Sponsors

collaborator

Palo Biofarma, S.L

INDUSTRY

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER